Insights Into Acute Myeloid Leukemia (AML)

Perspectives on management of newly diagnosed and relapsed/refractory AML

Meeting Chair

Elias Jabbour, MD

The University of Texas MD Anderson Cancer Center, Houston, TX, USA

Look Inside This Report

Download a sample of this report and start discovering the insights

Report Snapshot

Insights on the following AML therapies were obtained

  • azacitidine
  • cytarabine and daunorubicin (ie, 7+3)
  • decitabine
  • ivosidenib
  • enasidenib
  • gemtuzumab ozogamicin
  • gilteritinib
  • liposomal daunorubicin and cytarabine
  • midostaurin
  • sorafenib
  • venetoclax
  • glasdegib

GEOGRAPHIC REPRESENTATION & CONTENT DEVELOPMENT

  • A moderated roundtable discussion focusing on treatment of AML was held on October 26, 2019, in Seattle, WA
  • Disease state and data presentations were developed in conjunction with a medical expert from UC Davis
  • The group of advisors comprised 10 community oncologists
  • Data collection was accomplished through use of audience response system questioning and in-depth moderated discussion

Explore Available and Upcoming Insight Reports

View Reports